Switching among Equivalents in Chronic Cardiovascular Therapies: 'Real World' Data from Italy

Basic and Clinical Pharmacology and Toxicology

Volumn 118, Issue 1, 2016, Pages 63-69

  Poluzzi, Elisabetta ^a   Veronese, Giacomo ^a   Piccinni, Carlo ^a   Raschi, Emanuel ^a   Koci, Ariola ^a   Pagano, Paola ^b   Godman, Brian ^c,d   Marchesini, Giulio ^a   Boriani, Giuseppe ^a   De Ponti, Fabrizio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Bologna Health Trust   (Italy)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLECAINIDE; ORAL ANTIDIABETIC AGENT; PROPAFENONE; ANTIDIABETIC AGENT; GENERIC DRUG;

ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; HUMAN; ITALY; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; DRUG UTILIZATION REVIEW; ECONOMICS; FACTUAL DATABASE; FEMALE; MALE; REIMBURSEMENT; STANDARDS; STATISTICS AND NUMERICAL DATA; TRENDS;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; DRUG PRESCRIPTIONS; DRUG UTILIZATION REVIEW; DRUGS, GENERIC; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSURANCE, HEALTH, REIMBURSEMENT; ITALY; MALE;

EID: 84983163176     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12442     Document Type: Article

References (50)

1. Godman B, Wettermark B, van Woerkom M, Fraeyman J, varez-Madrazo S, Berg C, et al. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. Front Pharmacol 2014;5:106.
2. Garattini S, Bertele' V, Godman B, Haycox A, Wettermark B, Gustafsson LL. Enhancing the rational use of new medicines across European health care systems. Eur J Clin Pharmacol 2008;64:1137-8.
3. Kazrplan W, Wirtz V, Mantel-Teeuwisse A, Stolk P, Duthey B, Laing R. Priority medicines for Europe and the world 2013 update report. www.who.int 2013.
4. Godman B, Malmstrom RE, Diogene E, Gray A, Jayathissa S, Timoney A, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol 2015;8:77-94.
5. Kaiser J. Personalized medicine. New cystic fibrosis drug offers hope, at a price. Science 2012;335:645.
6. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013;121:4439-42.
7. Cohen JP, Felix A. Are payers treating orphan drugs differently? J Mark Access Health Policy 2014;2:23516.
8. Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: Justum Pretium-the just price. J Clin Oncol 2013;31:3600-4.
9. Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int J Clin Pract 2008;62:480-4.
10. Martikainen JE, Saastamoinen LK, Korhonen MJ, Enlund H, Helin-Salmivaara A. Impact of restricted reimbursement on the use of statins in Finland: a register-based study. Med Care 2010;48:761-6.
11. Sakshaug S, Furu K, Karlstad O, Ronning M, Skurtveit S. Switching statins in Norway after new reimbursement policy: a nationwide prescription study. Br J Clin Pharmacol 2007;64:476-81.
12. Voncina L, Strizrep T, Godman B, Bennie M, Bishop I, Campbell S, et al. Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future. Expert Rev Pharmacoecon Outcomes Res 2011;11:469-79.
13. Moon JC, Godman B, Petzold M, varez-Madrazo S, Bennett K, Bishop I, et al. Different initiatives across Europe to enhance losartan utilization post generics: impact and implications. Front Pharmacol 2014;5:219.
14. Cahir C, Fahey T, Tilson L, Teljeur C, Bennett K. Proton pump inhibitors: potential cost reductions by applying prescribing guidelines. BMC Health Serv Res 2012;12:408-12.
15. Heinze G, Hronsky M, Reichardt B, Baumgartel C, Mullner M, Bucsics A, et al. Potential savings in prescription drug costs for hypertension, hyperlipidemia, and diabetes mellitus by equivalent drug substitution in Austria: a nationwide cohort study. Appl Health Econ Health Policy 2015;13:193-205.
16. Dylst P, Vulto A, Simoens S. Analysis of European policy towards generic medicines. GaBI J 2014;3:34-5.
17. Vogler S, Zimmermann N. How do regional sickness funds encourage more rational use of medicines, including the increase of generic uptake? A case study from Austria. GaBI J 2013;2:65-75.
18. Dylst P, Vulto A, Godman B, Simoens S. Generic medicines: solutions for a sustainable drug market? Appl Health Econ Health Policy 2013;11:437-43.
19. Bennie M, Godman B, Bishop I, Campbell S. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev Pharmacoecon Outcomes Res 2012;12:125-30.
20. Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Rev Pharmacoecon Outcomes Res 2010;10:707-22.
21. Woerkom M, Piepenbrink H, Godman B, Metz J, Campbell S, Bennie M, et al. Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. J Comp Eff Res 2012;1:527-38.
22. Godman B, Wettermark B, Hoffmann M, Andersson K, Haycox A, Gustafsson LL. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev Pharmacoecon Outcomes Res 2009;9:65-83.
23. Andersson K, Sonesson C, Petzold M, Carlsten A, Lonnroth K. What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. Pharmacoepidemiol Drug Saf 2005;14:341-8.
24. Garuoliene K, Godman B, Gulbinovic J, Wettermark B, Haycox A. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev Pharmacoecon Outcomes Res 2011;11:343-9.
25. Godman B, Bishop I, Finlayson AE, Campbell S, Kwon HY, Bennie M. Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert Rev Pharmacoecon Outcomes Res 2013;13:469-82.
26. Godman B, Schwabe U, Selke G, Wettermark B. Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering drugs. Pharmacoeconomics 2009;27:435-8.
27. Barbui C, Conti V. Adherence to generic v. brand antidepressant treatment and the key role of health system factors. Epidemiol Psychiatr Sci 2014;24:1-4.
28. Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, DeLapp D, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med 2006;166:332-7.
29. Sermet C, Andrieu V, Godman B, Van GE, Haycox A, Reynier JP. Ongoing pharmaceutical reforms in France: implications for key stakeholder groups. Appl Health Econ Health Policy 2010;8:7-24.
30. Godman B, Abuelkhair M, Vitry A, Abdu S, Bennie M, Bishop I, et al. Payers endorse generics to enhance prescribing efficiency: impact and future implications, a case history approach. GaBI J 2012;1:69-83.
31. Vogler S. The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries-an overview. GaBI J 2012;1:93-100.
32. Garattini L, Ghislandi S. Off-patent drugs in Italy. A short-sighted view? Eur J Health Econ 2006;7:79-83.
33. Ghislandi S, Krulichova I, Garattini L. Pharmaceutical policy in Italy: towards a structural change? Health Policy 2005;72:53-63.
34. Vogler S. How large are the differences between originator and generic prices? Analysis of five molecules in 16 European countries. Farmeconomia Health Econ Therapeut Pathways 2012;13:29-41.
35. Cazrrone G, Schwierz C, Xavier A. Cost-containment policies in public pharmaceutical spending in the EU. Economic Papers 2012. 461.
36. Dunne S, Shannon B, Hannigan A, Dunne C, Cullen W. Physician and pharmacist perceptions of generic medicines: what they think and how they differ. Health Policy 2014;116:214-23.
37. Ferner RE, Lenney W, Marriott JF. Controversy over generic substitution. BMJ 2010;340:c2548.
38. Duerden MG, Hughes DA. Generic and therapeutic substitutions in the UK: are they a good thing? Br J Clin Pharmacol 2010;70:335-41.
39. Agenzia Italiana del Farmaco. L'uso dei farmaci in Italia - Rapporto OsMed 2013. http://www.agenziafarmaco.gov.it/it/content/luso-dei-farmaci-italia-rapporto-osmed-2013 (last accessed on 20 July 2015).
40. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002;27:299-309.
41. Godman B, Wettermark B, Miranda J, Bennie M, Martin A, Malmstrom RE. Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries. Int J Clin Pract 2013;67:853-62.
42. Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 2008;300:2514-26.
43. Corrao G, Soranna D, Merlino L, Mancia G. Similarity between generic and brand-name antihypertensive drugs for primary prevention of cardiovascular disease: evidence from a large population-based study. Eur J Clin Invest 2014;44:933-9.
44. Kesselheim AS, Stedman MR, Bubrick EJ, Gagne JJ, Misono AS, Lee JL, et al. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs 2010;70:605-21.
45. Perucca E, Albani F, Capovilla G, Bernardina BD, Michelucci R, Zaccara G. Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs. Epilepsia 2006;47(Suppl 5):16-20.
46. MHRA . Antiepileptic drugs: new advice on switching between different manufacturers' products for a particular drug. Drug Safety Update 2013;7:A1.
47. Olsson E, Kalvemark SS. Pharmacists' experiences and attitudes regarding generic drugs and generic substitution: two sides of the coin. Int J Pharm Pract 2012;20:377-83.
48. Martin A, Godman B, Miranda J, Tilstone J, Saleem N, Olsson E, et al. Measures to improve angiotensin receptor blocker prescribing efficiency in the UK: findings and implications. J Comp Eff Res 2014;3:41-51.
49. McGinn D, Godman B, Lonsdale J, Way R, Wettermark B, Haycox A. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications. Expert Rev Pharmacoecon Outcomes Res 2010;10:73-85.
50. Dylst P, Simoens S. Does the market share of generic medicines influence the price level?: a European analysis. Pharmacoeconomics 2011;29:875-82.